Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

While weight loss drugs have helped people shed several pounds, some have also reported excess hair fall. A Delhi-based dermatologist recommended what you should do, including natural supplements, red ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.